ACTRN12608000500358
Completed
未知
A clinical trial assessing the efficacy and neural mechanisms of Remotiv (Ze117), nicotine patches and combination Remotiv/nicotine patches for smoking cessation.
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Swinburne University of Technology
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Smoking for at least 5 years; currently smoking at least 10 cigarettes per day;
- •Motivated to quit smoking; not currently (or in the past 6 months) taking Hypericum perforatum or anti\-depressants
Exclusion Criteria
- •History of anxiety or depression; currently using nicotine replacement therapy; kidney or liver disease; high blood pressure; diabetes
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
To evaluate the effectiveness of Amukkara chooranam and aya chenduram in the management of aan maladuHealth Condition 1: - Health Condition 2: - Health Condition 3: N461- OligospermiaCTRI/2024/04/065757DrSESWARI
Not yet recruiting
Phase 2
The effect of the remaining bony walls of the maxillary sinus on the quality of the formed bone in dental implantsTeeth implants.Presence of other specified functional implantsZ96.8IRCT20210204050239N1Mashhad University of Medical Sciences40
Recruiting
Phase 3
Assessing the effectiveness of topical peppermint cream and orally ingestible peppermint oxymel mouthwash on halitosis and vomiting of breast cancer patients during chemotherapyBreast cancer patients treated with chemotherapy drugs.Malignant neoplasm of breastIRCT20201219049763N1Iranian academic center for education culture and research225
Recruiting
Not Applicable
A clinical trial investigating the effectiveness of a new tooth- and bone-borne rapid expansion deviceJaw deformitymaxillary transverse deficiencyD007569JPRN-jRCTs062210075Kamioka Hiroshi10
Recruiting
Not Applicable
The clinical trial to examine the efficacy of the intravitreal injection of anti-VEGF antibody Bevacizumab(Avastin) for severe retinopathy of prematurity.Retinopathy of prematurityJPRN-UMIN000018069Gunma University Hospital Department of Ophthalmology4